Form 8-K · Current report
News Corp 8-K, filed Oct 21, 2026
- Filed
- CIK
- 0001564708
- Accession no.
- 0001564708-26-000233
Summary
News Corp repurchased 54,641 Class A common shares for about US$1.67 million on 20 October 2026 under its 2025 Repurchase Program, which authorizes up to US$1 billion of Class A and Class B common stock. The company has bought back roughly US$542.9 million worth of Class A and Class B shares under the program to date.
Key points
- The 2025 Repurchase Program, authorized as of July 15, 2025, permits repurchases of up to an aggregate US$1 billion of News Corp's Nasdaq-listed Class A and Class B common stock.
- Cumulative Class A shares bought back as of the previous day totaled 13,446,956, at a total consideration of about US$354.95 million.
- The highest price paid for Class A shares in the program was US$31.58 (27 August 2026) and the lowest was US$22.20 (9 February 2026).
- News Corp said the buy-back's purpose is to enhance shareholder value, with no shareholder approval required.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 8.01 Other Events. As previously reported, under News Corporation's (the "Company's") stock repurchase program (the "Repurchase Program"), the Company is authorized to acquire from time to time up to $1 billion in the aggregate of the Company's outstanding shares of Class A common stock and Class B common stock. Under the rules of the Australian Securities Exchange (the "ASX"), the Company is required to provide to the ASX, on a daily basis, disclosure of transactions pursuant to the Repurchase Program, if any. The Company also discloses information concerning the Repurchase Program in the Company's quarterly and annual reports. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.